Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate
The utilization of antibody–drug conjugates (ADCs) has gained considerable attention in the field of targeted cancer therapy due to their ability to synergistically combine the specificity of monoclonal antibodies (mAbs) and the potency of small molecular drugs. However, the immunogenic nature of the antibody component within ADCs warrants the need for robust immunogenicity testing, including a neutralizing antibody (NAb) assay. Since the mechanism of action (MOA) of the ADC is to first bind to the target cells and then release the payload intracellularly to kill the cells, the most relevant NAb assay format would be a cell-based killing assay. However, in this paper, we present a case where a cell-based killing assay could not be developed after multiple cell lines and NAb-positive controls (PC) had been tested. Surprisingly, contrary to our expectations, all NAb PCs tested exhibited an increased killing effect on the target cells, instead of the expected protective response. This unexpected phenomenon most likely is due to the non-specific internalization of drug/NAb complexes via FcγRs, as an excessive amount of human IgG1 and mouse IgG2a, but not mouse IgG1, greatly inhibited drug or drug/NAb complexes induced cell death. To overcome this obstacle, we implemented a novel cell-based binding assay utilizing the Meso Scale Discovery (MSD) platform. We also propose that an in vitro cell killing NAb assay is limited to at best monitoring the target binding and internalization induced cell death, but not by-stander killing induced by prematurely released or dead-cell released payload, hence cannot really mimic the in vivo MOA of ADC. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The AAPS Journal - 26(2024), 3 vom: 28. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Weifeng [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antibody–drug conjugate (ADC) |
| Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1208/s12248-024-00909-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055336825 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055336825 | ||
| 003 | DE-627 | ||
| 005 | 20240412064635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12248-024-00909-7 |2 doi | |
| 035 | |a (DE-627)SPR055336825 | ||
| 035 | |a (SPR)s12248-024-00909-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Xu, Weifeng |e verfasserin |0 (orcid)0000-0001-7598-1489 |4 aut | |
| 245 | 1 | 0 | |a Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a The utilization of antibody–drug conjugates (ADCs) has gained considerable attention in the field of targeted cancer therapy due to their ability to synergistically combine the specificity of monoclonal antibodies (mAbs) and the potency of small molecular drugs. However, the immunogenic nature of the antibody component within ADCs warrants the need for robust immunogenicity testing, including a neutralizing antibody (NAb) assay. Since the mechanism of action (MOA) of the ADC is to first bind to the target cells and then release the payload intracellularly to kill the cells, the most relevant NAb assay format would be a cell-based killing assay. However, in this paper, we present a case where a cell-based killing assay could not be developed after multiple cell lines and NAb-positive controls (PC) had been tested. Surprisingly, contrary to our expectations, all NAb PCs tested exhibited an increased killing effect on the target cells, instead of the expected protective response. This unexpected phenomenon most likely is due to the non-specific internalization of drug/NAb complexes via FcγRs, as an excessive amount of human IgG1 and mouse IgG2a, but not mouse IgG1, greatly inhibited drug or drug/NAb complexes induced cell death. To overcome this obstacle, we implemented a novel cell-based binding assay utilizing the Meso Scale Discovery (MSD) platform. We also propose that an in vitro cell killing NAb assay is limited to at best monitoring the target binding and internalization induced cell death, but not by-stander killing induced by prematurely released or dead-cell released payload, hence cannot really mimic the in vivo MOA of ADC. Graphical Abstract | ||
| 650 | 4 | |a antibody–drug conjugate (ADC) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a cell-based killing assay |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fc receptors (FcγRs) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a immunogenicity testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Meso Scale Discovery (MSD) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a neutralizing antibody (NAb) |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bano, Nazneen |e verfasserin |4 aut | |
| 700 | 1 | |a Guzman-Valdes, Olguitza |e verfasserin |4 aut | |
| 700 | 1 | |a Amberman, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Bandlamudi, Elisha |e verfasserin |4 aut | |
| 700 | 1 | |a Khanna, Pooja |e verfasserin |4 aut | |
| 700 | 1 | |a Carmean, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Helmy, Roy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The AAPS Journal |d Springer International Publishing, 2004 |g 26(2024), 3 vom: 28. März |h Online-Ressource |w (DE-627)SPR055134424 |w (DE-600)2170248-2 |w (DE-576)281264910 |x 1550-7416 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:3 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12248-024-00909-7 |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 3 |b 28 |c 03 | ||